Congress: Alzheimer's Association International Conference (AAIC) 2026
Dates: July 12-15, 2026
Location: ExCeL London, UK
Theme: Building the Roadmap to 2030
Neurovascular dysfunction has emerged as a critical contributor to Alzheimer's disease (AD) pathogenesis, with mounting evidence that vascular and neurodegenerative processes interact in a self-amplifying cycle. At AAIC 2026, researchers are presenting groundbreaking findings on cerebral blood flow alterations, blood-brain barrier (BBB) breakdown, and therapeutic approaches targeting the neurovascular unit (NVU). This page covers the key sessions and research highlights on neurovascular contributions to AD, synthesizing recent findings with established mechanistic understanding.
The recognition that AD is not solely a neurodegenerative disease but also involves significant vascular pathology has fundamentally shifted the therapeutic landscape. The neurovascular unit — comprising endothelial cells, pericytes, astrocytes, and microglia — represents both a therapeutic target and a pathway to understand disease progression. Research presented at AAIC 2026 highlights how vascular dysfunction precedes and accelerates amyloid and tau pathology, offering opportunities for early intervention.
The neurovascular unit (NVU) is the functional multicellular complex that couples neuronal activity to local cerebral blood flow, maintains blood-brain-barrier integrity, and regulates the exchange of nutrients, oxygen, and metabolic waste between the brain and the vasculature. The NVU comprises endothelial-cells, pericytes, astrocytes, and microglia, all working in concert to maintain brain homeostasis. [1]
Each component of the NVU plays distinct yet interconnected roles in maintaining brain health:
Endothelial cells form the structural core of the BBB through continuous tight junctions (claudins, occludin, ZO-1), adherens junctions, and specialized transport systems. Brain endothelial cells express abundant efflux transporters (P-glycoprotein, BCRP) and maintain minimal transcytosis, creating a highly selective barrier. [2]
Pericytes ensheath brain capillaries, sharing a basement membrane with endothelial cells. They play essential roles in BBB maintenance, capillary blood flow regulation, and clearance of toxic metabolites. Brain pericytes are the most abundant among all organs, with a pericyte-to-endothelial cell ratio of approximately 1:1 to 1:3.
Astrocytes extend specialized endfeet covering approximately 99% of the brain capillary surface. Through these endfeet, astrocytes regulate water homeostasis via aquaporin-4 (AQP4) channels, modulate tight junction integrity, and control neurovascular coupling. [3]
Microglia play crucial roles in immune surveillance and vascular homeostasis, responding to pathological changes and contributing to neuroinflammation that affects NVU function.
The two-hit vascular hypothesis proposes that vascular risk factors (hit 1) damage the NVU, which then fails to clear amyloid-beta (hit 2), initiating a self-amplifying cycle of vascular damage and amyloid accumulation. [4] This model has gained substantial support from clinical and experimental evidence presented at AAIC meetings in recent years.
Key NVU changes in AD include:
Blood-brain-barrier breakdown: Occurs in the hippocampus and entorhinal cortex early in AD, detectable by dynamic contrast-enhanced MRI and CSF biomarkers. [5]
Pericyte degeneration: Loss of pericytes correlates with tau pathology and cognitive decline. Soluble PDGFRβ (sPDGFRβ) in CSF has emerged as a biomarker of NVU dysfunction. Pericyte loss is one of the earliest vascular changes in AD and aging. [6]
Impaired amyloid clearance: The NVU clears amyloid-β via LRP1-mediated transcytosis, enzymatic degradation (neprilysin, insulin-degrading enzyme), and perivascular drainage. These pathways decline with NVU dysfunction.
Cerebral hypoperfusion: Reduced blood flow precedes clinical AD by years and contributes to neuronal energy failure.
Impaired glymphatic clearance: Loss of AQP4 polarization reduces waste removal of amyloid-β and tau. [7]
Cerebral hypoperfusion represents one of the earliest detectable changes in AD, often preceding clinical symptoms by years to decades. Research presented at AAIC 2026 highlights how reduced cerebral blood flow (CBF) creates regions of relative hypoxia that exacerbate neuronal vulnerability and accelerate protein aggregation.
Regional CBF reductions in AD typically affect:
These patterns correlate with glucose hypometabolism observed in FDG-PET scans and precede amyloid deposition in many patients. The vascular hypothesis of AD suggests that reduced CBF is not merely a consequence of neurodegeneration but an active driver of disease progression.
Neurovascular coupling — also termed functional hyperemia — is the process by which neural activity triggers localized increases in cerebral blood flow. This coupling is essential for delivering oxygen and glucose to active neurons and for removing metabolic waste. [8]
Neurovascular coupling is impaired early in AD, vascular dementia, and cerebral small vessel disease. Functional MRI studies consistently show reduced hemodynamic responses to neural activation in AD patients. This impairment:
The mechanisms underlying impaired neurovascular coupling include:
Research from AAIC 2026 highlights novel imaging approaches to detect early neurovascular coupling deficits, including advanced ASL-MRI techniques and optogenetic methods in preclinical models. [9]
BBB breakdown is an early biomarker of human cognitive dysfunction, detectable before clinical symptoms appear. [5:1] Key findings from recent studies include:
Regional vulnerability: The hippocampus and entorhinal cortex show early BBB leakage in humans with early AD, even in the absence of overt cognitive symptoms.
Fluid biomarkers: CSF albumin quotient (Qalb), sPDGFRβ, and fibrinogen serve as indicators of BBB permeability and pericyte injury.
Imaging biomarkers: Dynamic contrast-enhanced (DCE) MRI quantifies BBB permeability (Ktrans) in specific brain regions, enabling early detection.
Multiple mechanisms contribute to BBB dysfunction in AD:
Tight junction disruption: Downregulation and mislocalization of claudin-5, occludin, and ZO-1 compromise the paracellular barrier.
Increased transcytosis: Elevated rates of caveolae-mediated transcytosis allow plasma proteins to enter the brain parenchyma.
Endothelial activation: Upregulation of adhesion molecules (ICAM-1, VCAM-1) facilitates peripheral immune cell infiltration.
Pericyte loss: Reduced pericyte coverage correlates with increased BBB permeability and cognitive decline.
Basement membrane degradation: Matrix metalloproteinases (MMP-2, MMP-9) degrade the vascular basement membrane. [10]
The BBB expresses specific transporters that regulate amyloid-β bidirectional transport:
This imbalance creates a net influx of amyloid-β into the brain parenchyma, accelerating plaque formation. Therapeutic strategies targeting these transport pathways are under active investigation.
| Biomarker | Source | Significance |
|---|---|---|
| sPDGFRβ | CSF | Pericyte injury and BBB breakdown |
| Albumin quotient (Qalb) | CSF/serum | BBB permeability |
| Fibrinogen in CSF | CSF | BBB leakage of plasma proteins |
| GFAP | Blood/CSF | Astrocytic reactivity |
| MMP-9 | Blood/CSF | Basement membrane degradation |
| VEGF-A | Blood/CSF | Angiogenic signaling |
The MARKVCID consortium is developing and validating vascular contributions to cognitive impairment and dementia (VaD) biomarkers, with several candidates entering clinical validation. [11]
Modifiable vascular risk factors — hypertension, diabetes, hypercholesterolemia, smoking, and obesity — contribute to NVU dysfunction. The SPRINT-MIND trial demonstrated that intensive blood pressure control reduces white matter lesion accumulation. GLP-1 receptor agonists show pleiotropic vascular protective effects through anti-inflammatory and metabolic benefits.
Single-cell vascular atlases: Mapping cell-type-specific transcriptomic changes across disease stages
Brain-on-a-chip models: Microfluidic NVU models for drug screening
Multi-target NVU restoration: Strategies that simultaneously address endothelial, pericyte, astrocytic, and microglial components. [12]
Vascular contributions to mixed pathology: Understanding how vascular dysfunction interacts with amyloid and tau
Early intervention windows: Identifying optimal timing for NVU-targeted therapies
Several trials targeting NVU components are underway:
The neurovascular dysfunction in AD connects to multiple other wiki pages:
Mechanisms: Neurovascular Unit, Blood-Brain Barrier Dysfunction, Neurovascular Coupling, Vascular Contributions to AD, Glymphatic System Dysfunction
Proteins: Amyloid-Beta, Tau, LRP1, RAGE, VEGF
Cell Types: Pericytes, Endothelial Cells, Astrocytes, Microglia
Diseases: Alzheimer's Disease, Vascular Dementia, Cerebral Small Vessel Disease, Cerebral Amyloid Angiopathy
Therapeutics: Pericyte PDGFR/VEGFR Modulator Therapy, Glymphatic CSF Enhancement Therapy, Focused Ultrasound
Neurovascular dysfunction represents a central feature of AD pathogenesis that interacts with amyloid and tau pathology in complex ways. Research at AAIC 2026 highlights:
The integration of neurovascular concepts into AD research represents a paradigm shift from viewing AD as purely neurodegenerative to understanding it as a multi-system disorder requiring integrated therapeutic approaches.
Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathologica. 2010. ↩︎
Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer's disease and other neurodegenerative disorders. Nature Reviews Neurology. 2018. ↩︎
Iadecola C. The neurovascular unit coming of age: A journey through neurovascular coupling in health and disease. Neuron. 2017. ↩︎
Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nature Reviews Neuroscience. 2011. ↩︎
Nation DA, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine. 2019. ↩︎ ↩︎
Kisler K, et al. The neurovascular unit dysfunction in Alzheimer's disease. International Journal of Molecular Sciences. 2021. ↩︎
Carvalho C, Bhatt P. Neurovascular Dysfunction and Glymphatic Impairment: An Unexplored Therapeutic Frontier in Neurodegeneration. International Journal of Molecular Sciences. 2025. ↩︎
Attwell D, et al. Glial and neuronal control of brain blood flow. Nature. 2010. ↩︎
Engelen T, et al. Physiological basis of neurovascular coupling in brain disease. Nature Reviews Neurology. 2023. ↩︎
Shin Y, et al. Blood-brain barrier dysfunction in AD: From mechanism to therapy. Nature Reviews Drug Discovery. 2023. ↩︎
Van Dyken P, et al. Vascular contributions to cognitive impairment and dementia: MARKVCID. Nature Reviews Neurology. 2020. ↩︎
Li Y, et al. Crossing Pathological Boundaries: Multi-Target Restoration of the Neurovascular Unit in Alzheimer's and Vascular Dementia. Aging and Disease. 2025. ↩︎